A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

A  scientific forum held in HCM City on April 27 announced a pioneering preventive method to help prevent lower respiratory ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...